VEGFA and renal cell carcinoma: Vascular endothelial growth factor (VEGF)-targeted therapy, which is the standard of care for metastatic clear cell RCC in a first-line setting, have yielded variable efficacy in Xp11.2 RCC in published studies12, 17, 18.